Clovis Oncology Inc (CLVS) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $-2.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.32. Analysts had a consensus of $-2.49. During the same quarter in the previous year, the company posted $-1.86 EPS.
Many Wall Street Analysts have commented on Clovis Oncology Inc. Shares were Reiterated by Mizuho on Apr 13, 2016 to “Neutral” and Lowered the Price Target to $ 15 from a previous price target of $21 .Clovis Oncology Inc was Downgraded by JP Morgan to ” Neutral” on Apr 13, 2016. Clovis Oncology Inc was Downgraded by Credit Suisse to ” Neutral” on Apr 13, 2016.
Clovis Oncology Inc closed down -0.76 points or -5.45% at $13.19 with 10,52,367 shares getting traded on Wednesday. Post opening the session at $13.78, the shares hit an intraday low of $12.94 and an intraday high of $14.01 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at $104.18 per share price. According to the SEC, on Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at $97.80 per share price. On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at $91.91 per share price, according to the Form-4 filing with the securities and exchange commission.
Clovis Oncology Inc. (Clovis) is a biopharmaceutical company focused on acquiring developing and commercializing anti-cancer agents in the United States Europe and additional international markets. The Company is developing three product candidates: Rociletinib Rucaparib and Lucitanib. Rociletinib an oral epidermal growth factor receptor (EGFR) is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib an oral inhibitor of poly (ADP-ribose) polymerase (PARP) is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3) vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.